Biotech


  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Leqembi sales inch higher; Spark’s pivot leads to layoffs

    Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

    By BioPharma Dive staff • July 12, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    AbbVie names new R&D head; Arcutis eczema cream approved

    Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.

    By BioPharma Dive staff • July 10, 2024
  • Explore the Trendline
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • A person in a blue suit speaks at a lectern.
    Image attribution tooltip
    Jerod Harris via Getty Images
    Image attribution tooltip

    Flagship raises $3.6B for biotech investing

    The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.

    By Kristin Jensen • July 10, 2024
  • A photograph of Amylyx Pharmaceuticals cofounders Josh Cohen and Justin Klee.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx, with GLP-1 buy, doubles down on blood sugar drugs

    Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

    By July 10, 2024
  • A woman's hands over her abdomen.
    Image attribution tooltip
    Doucefleur via Getty Images
    Image attribution tooltip
    Emerging biotech

    SciRhom pulls in $70M for a new type of immune disease drug

    The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.

    By July 9, 2024
  • People stand on a dock below a large cruise ship
    Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    HilleVax’s norovirus vaccine ineffective in large trial of infants

    Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.

    By July 8, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Ligand to buy Apeiron; Roche reports another TIGIT setback

    Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.

    By BioPharma Dive staff • July 8, 2024
  • Myricx Bio co-founders Andrew Bell, Roberto Solari and Ed Tate, and CEO Robin Carr in a laboratory.
    Image attribution tooltip
    Permission granted by Myricx Bio
    Image attribution tooltip

    A London biotech raises $114M to hone a new ADC payload

    Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.

    By July 8, 2024
  • Employees of CureVac work in a laboratory
    Image attribution tooltip
    Courtesy of CureVac
    Image attribution tooltip

    CureVac cuts jobs, licenses out vaccines to GSK

    The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

    By July 3, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit

    Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.

    By BioPharma Dive staff • July 3, 2024
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna gets US funding for bird flu vaccine development

    BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.

    By July 2, 2024
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Eli Lilly inks another radiopharma deal, gaining option to buy startup

    Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.

    By July 1, 2024
  • Employees of biotechnology company UniQure work in a laboratory.
    Image attribution tooltip
    Courtesy of UniQure
    Image attribution tooltip

    UniQure, with sale of plant, outsources Hemgenix manufacturing

    The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.

    By July 1, 2024
  • 3D Rendering of a Natural Killer Cell (NK Cell) destroying a cancer cell.
    Image attribution tooltip
    Marcin Klapczynski via Getty Images
    Image attribution tooltip

    With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease

    Like many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its strategy to ride a wave of investor interest in autoimmune disease research.

    By July 1, 2024
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    10 clinical trials to watch in the second half of 2024

    Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

    By BioPharma Dive staff • July 1, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

    European drug regulators voted for a third time not to renew the approval of Translarna. Elsewhere, Sanofi invested in a brain disease biotech and Esperion sold royalties to help pay off a loan. 

    By BioPharma Dive staff • June 28, 2024
  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip
    Emerging biotech

    ​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work

    Alumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold fewer shares than intended, and added a concurrent private stock issuance to boost its total haul. 

    By June 28, 2024
  • A photo of Bluebird bio employees in a laboratory.
    Image attribution tooltip
    Courtesy of Bluebird bio
    Image attribution tooltip

    2seventy slims down with sale of hemophilia assets to Novo

    Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.

    By June 27, 2024
  • An ion channel, colored yellow, is embedded in a cell membrane in this illustration.
    Image attribution tooltip
    Permission granted by Biohaven Ltd.
    Image attribution tooltip
    Deep Dive

    These microscopic tunnels are a goldmine for new medicines

    A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.

    By June 27, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s

    Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged. 

    By BioPharma Dive staff • June 26, 2024
  • Faye Feller, executive vice president, chief medical officer, Geron
    Image attribution tooltip
    Permission granted by Geron
    Image attribution tooltip

    After 33 years, Geron’s first approval marks a turn in Nobel-winning science

    The decades-long story of how a novel type of blood cancer drug went from a scientific idea to an approved product.

    By Alexandra Pecci • June 26, 2024
  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Olena_T via Getty Images
    Image attribution tooltip
    Emerging biotech

    Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine

    The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.

    By June 25, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

    The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.

    By BioPharma Dive staff • June 24, 2024
  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Ivan-Balvan via Getty Images
    Image attribution tooltip

    Alnylam says heart drug succeeds in closely watched study

    Positive results from a Phase 3 trial of vutrisiran in transthyretin amyloidosis cardiomyopathy come eight months after the FDA rejected another medicine Alnylam developed for the condition.

    By Updated June 24, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

    A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.

    By BioPharma Dive staff • June 21, 2024